ArticleFrontiers in medicine2025
The rising burden of Alzheimer's and other dementias: role of high fasting plasma glucose from 1990 to 2021.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The divergent effects of population aging: comparative analysis of the burden of Alzheimer's disease and other dementias in China and G20 countries, 1990-2050.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dementia, one of the top 10 causes of death globally, imposes significant health and socioeconomic/socioeconomic burdens, with prevalence projected to reach 82 million by 2030. High fasting plasma glucose (HFPG) is a prominent modifiable risk factor for dementia in 2021. This study aims first to examine the global trend in dementia burden and the disability-adjusted life years and death attributable to HFPG from 1990 to 2021 and second to define age-specific disparities in dementia burden among older populations. Methods: Using data from the Global Burden of Diseases Study (GBD) 2021, this research evaluated the incidence, prevalence, deaths, disability-adjusted life years (DALYs), and HFPG-attributable burden related to Alzheimer's disease and other dementias (ADOD). The estimated annual percentage change was calculated to qualify the burden change of ADOD. Results: There was a significant rise in the ADOD burden globally, with over 56.9 million prevalent cases and 2.0 million deaths in 2021. the incidence and prevalence were positively correlated with HFPG-related summary exposure value. The HFPG-attributable ADOD burden has increased worldwide over time. Globally, the 60 to 74 age groups suffered a prominent rise in the burden and HFPG-attributable burden of ADOD. Conclusion: The global burden and HFPG-attributable ADOD burden have remained prominent and have increased increase over the past 32 years. The ASIR and ASPR showed positive correlations with the SEV related to HFPG. Notably, the 60 to 74 age groups suffered a prominent rise in burden and HFPG attributable to the DALYs rate of ADOD over time. Moreover, a prominent positive correlation was observed between the incidence and prevalence rate with the SEVs related to HFPG occurred in the population aged 60 to 74 years old. Therefore, HFPG should be emphasized in strategic priorities for controlling the ADOD burden.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.